The capabilities of our platform and experts shift to meet your needs:
- eCOA Oncology library
- Built-in notifications and reminders
- Life-long follow up through tokenization
- Customer onboarding and support
- Protocol consulting and design by oncology and eCOA trial experts
Powered by Medable
ROI for Phase III trials*
Emerging Biopharma + biotech companies
of the top CROs as partners
The Tufts Center for the Study of Drug Development: Impact Report
Findings from Tufts CSDD show net financial benefits range from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively. Download the report to learn more.
The latest from Medable
What does the new European Medicine Regulatory Network recommendation paper on decentralized elements in clinical trials tell us?
Learn what impacts the new European Medicine Regulatory Network recommendations paper means to your clinical trial operations.
New EU Regulatory Recommendations for Decentralized Trials Keep Focus on Patients and Sites
As clinical trials rapidly modernize, government regulators work to evolve even as the same core principles apply. Still, decentralized clinical trials are – simply – clinical trials, as all research today is decentralized in some way, yet we lack global harmonization of regulations.